Polycystic Ovary Syndrome: A Comprehensive Review of Pathogenesis, Management, and Drug Repurposing
Open accessThe DOI matches its Crossref record; 106 of the 106 references it cites were found in a registry or an index.
Abstract
Polycystic ovary syndrome (PCOS) is an endocrine-gynecology disorder affecting many women of childbearing age. Although a part of the involved mechanism in PCOS occurrence is discovered, the exact etiology and pathophysiology are not comprehensively understood yet. We searched PubMed for PCOS pathogenesis and management in this article and ClinicalTrials.gov for information on repurposed medications. All responsible factors behind PCOS were thoroughly evaluated. Furthermore, the complete information on PCOS commonly prescribed and repurposed medications is summarized through tables. Epigenetics, environmental toxicants, stress, diet as external factors, insulin resistance, hyperandrogenism, inflammation, oxidative stress, and obesity as internal factors were investigated. Lifestyle modifications and complementary and alternative medicines are preferred first-line therapy in many cases. Medications, including 3-hydroxy-3-methyl-3-glutaryl-coenzyme A (HMG-CoA) reductase inhibitors, thiazolidinediones, sodium-glucose cotransporter-2 inhibitors, dipeptidyl peptidase-4 inhibitors, glucose-like peptide-1 receptor agonists, mucolytic agents, and some supplements have supporting data for being repurposed in PCOS. Since there are few completed clinical trials with a low population and mostly without results on PCOS repurposed medications, it would be helpful to do further research and run well-designed clinical trials on this subject. Moreover, understanding more about PCOS would be beneficial to find new medications implying the effect via the novel discovered routes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Hyperandrogenism, hyperinsulinism and insulin resistance (IR) are the main drivers of clinical, metabolic and reproductive phenotypes of PCOS.”
From Low-Calorie Ketogenic Diet: Potential Application in the Treatment of Polycystic Ovary Syndrome in Adolescents (2023) · cites this paper as [3]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Similarly, the DAI has been developed as a more specific measure of adipose tissue dysfunction by combining WC, BMI, TG levels, and HDL-C [9,10,11].”
From Visceral and Dysfunctional Adiposity Indices as Predictors of Insulin Resistance and Metabolic Syndrome in Women with Polycystic Ovary Syndrome: A Cross-Sectional Study (2025) · cites this paper as [10]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“The VAI is an established marker of abdominal obesity and IR, integrating WC, triglyceride (TG) levels, and high-density lipoprotein cholesterol (HDL-C) to predict metabolic risk.”
From Visceral and Dysfunctional Adiposity Indices as Predictors of Insulin Resistance and Metabolic Syndrome in Women with Polycystic Ovary Syndrome: A Cross-Sectional Study (2025) · cites this paper as [10]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Polycystic Ovary Syndrome: Definition, Aetiology, Diagnosis and Treatment
Escobar-Morreale, H. F. (2018) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2018.24 · Cited by 2,083
Rosenfield, R. L., & Ehrmann, D. A. (2016) · Endocrine Reviews · doi:10.1210/er.2015-1104 · Cited by 1,603
Chronic Low Grade Inflammation in Pathogenesis of PCOS
Rudnicka, E., Suchta, K., Grymowicz, M., Calik-Ksepka, A., Smolarczyk, K., Duszewska, A. M., Smolarczyk, R., & Meczekalski, B. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22073789 · Cited by 680
Witchel, S. F., Oberfield, S. E., & Peña, A. S. (2019) · Journal of the Endocrine Society · doi:10.1210/js.2019-00078 · Cited by 653
Sanchez-Garrido, M. A., & Tena-Sempere, M. (2020) · Molecular Metabolism · doi:10.1016/j.molmet.2020.01.001 · Cited by 557
Polycystic Ovarian Syndrome: Correlation Between Hyperandrogenism, Insulin Resistance and Obesity.
Zeng, X., Xie, Y.-J., Liu, Y.-T., Long, S.-L., & Mo, Z.-C. (2020) · Clinica Chimica Acta · doi:10.1016/j.cca.2019.11.003 · Cited by 525
A novel and compact review on the role of oxidative stress in female reproduction
Lu, J., Wang, Z., Cao, J., Chen, Y., & Dong, Y. (2018) · Reproductive Biology and Endocrinology · doi:10.1186/s12958-018-0391-5 · Cited by 481
Ibáñez, L., Oberfield, S. E., Witchel, S., Auchus, R. J., Chang, R. J., Codner, E., Dabadghao, P., Darendeliler, F., Elbarbary, N. S., Gambineri, A., et al. (2017) · Hormone Research in Paediatrics · doi:10.1159/000479371 · Cited by 463
Characteristics of obesity in polycystic ovary syndrome: Etiology, treatment, and genetics
Glueck, C. J., & Goldenberg, N. (2019) · Metabolism · doi:10.1016/j.metabol.2018.11.002 · Cited by 442 · cited 3×
“Excess abdominal fat is also responsible for the inflammatory condition [6,44,81].”
BackgroundCassar, S., Misso, M. L., Hopkins, W. G., Shaw, C. S., Teede, H. J., & Stepto, N. K. (2016) · Human Reproduction · doi:10.1093/humrep/dew243 · Cited by 415 · cited 1×
“On the other hand, hyperinsulinemia reduces hepatic SHBG [18,32,40,49,52,54–56], increasing free testosterone levels in blood [18,32,52,54,56].”
BackgroundObesity, Polycystic Ovary Syndrome, and Infertility: A New Avenue for GLP-1 Receptor Agonists
Cena, H., Chiovato, L., & Nappi, R. E. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa285 · Cited by 356
Hyperandrogenemia and insulin resistance: The chief culprit of polycystic ovary syndrome
Wang, J., Wu, D., Guo, H., & Li, M. (2019) · Life Sciences · doi:10.1016/j.lfs.2019.116940 · Cited by 322
Roles of oxidative stress in polycystic ovary syndrome and cancers
Zuo, T., Zhu, M., & Xu, W. (2016) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2016/8589318 · Cited by 319
He, F.-F., & Li, Y.-M. (2020) · Journal of Ovarian Research · doi:10.1186/s13048-020-00670-3 · Cited by 289
The pathogenesis and treatment of polycystic ovary syndrome: What’s new?
Bednarska, S., & Siejka, A. (2017) · Advances in Clinical and Experimental Medicine · doi:10.17219/acem/59380 · Cited by 284
Pilot study of resveratrol in older adults with impaired glucose tolerance
Crandall, J. P., Oram, V., Trandafirescu, G., Reid, M., Kishore, P., Hawkins, M., Cohen, H. W., & Barzilai, N. (2012) · The Journals of Gerontology: Series A · doi:10.1093/gerona/glr235 · Cited by 281
Insulin and the polycystic ovary syndrome
Macut, D., Bjekić-Macut, J., Rahelić, D., & Doknić, M. (2017) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2017.06.011 · Cited by 261
New markers of insulin resistance in polycystic ovary syndrome
Polak, K., Czyzyk, A., Simoncini, T., & Meczekalski, B. (2017) · Journal of Endocrinological Investigation · doi:10.1007/s40618-016-0523-8 · Cited by 256
Epidemiology, pathogenesis, genetics & management of polycystic ovary syndrome in India
Ganie, M. A., Vasudevan, V., Wani, I. A., Baba, M. S., Arif, T., & Rashid, A. (2019) · Indian Journal of Medical Research · doi:10.4103/ijmr.ijmr_1937_17 · Cited by 232
Depression, anxiety and perceived stress in women with and without PCOS: a community-based study
Damone, A. L., Joham, A. E., Loxton, D., Earnest, A., Teede, H. J., & Moran, L. J. (2019) · Psychological Medicine · doi:10.1017/s0033291718002076 · Cited by 230
Adipose Tissue-Derived Omentin-1 Function and Regulation
Watanabe, T., Watanabe‐Kominato, K., Takahashi, Y., Kojima, M., & Watanabe, R. (2017) · Comprehensive physiology · doi:10.1002/cphy.c160043 · Cited by 210
Li, Y., Chen, C., Ma, Y., Xiao, J., Luo, G., Li, Y., & Wu, D. (2019) · Life Sciences · doi:10.1016/j.lfs.2019.04.046 · Cited by 198
Jeanes, Y. M., & Reeves, S. (2017) · Nutrition Research Reviews · doi:10.1017/s0954422416000287 · Cited by 194
Environmental determinants of polycystic ovary syndrome
Merkin, S. S., Phy, J. L., Sites, C. K., & Yang, D. (2016) · Fertility and Sterility · doi:10.1016/j.fertnstert.2016.05.011 · Cited by 193
Polycystic ovary syndrome and environmental toxins
Rutkowska, A. Z., & Diamanti-Kandarakis, E. (2016) · Fertility and Sterility · doi:10.1016/j.fertnstert.2016.08.031 · Cited by 192
Endocrine Disruptors Leading to Obesity and Related Diseases
Petrakis, D., Vassilopoulou, L., Mamoulakis, C., Psycharakis, C., Anifantaki, A., Sifakis, S., Docea, A., Tsiaoussis, J., Makrigiannakis, A., & Tsatsakis, A. (2017) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph14101282 · Cited by 192
Self-citationEffect of Exercise on Ovulation: A Systematic Review
Hakimi, O., & Cameron, L. C. (2016) · Sports Medicine · doi:10.1007/s40279-016-0669-8 · Cited by 191
Editor, R. (2023) · Reproductive Endocrinology · doi:10.18370/2309-4117.2023.69.59-79 · Cited by 188
Liu, Y., Liu, H., Li, Z., Fan, H., Yan, X., Liu, X., Xuan, J., Feng, D., & Wei, X. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.685724 · Cited by 186
Chronic stress and body composition disorders: implications for health and disease
Stefanaki, C., Pervanidou, P., Boschiero, D., & Chrousos, G. P. (2018) · HORMONES · doi:10.1007/s42000-018-0023-7 · Cited by 183
Mancini, A., Bruno, C., Vergani, E., d’Abate, C., Giacchi, E., & Silvestrini, A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22041667 · Cited by 177
Shorakae, S., Ranasinha, S., Abell, S., Lambert, G., Lambert, E., de Courten, B., & Teede, H. (2018) · Clinical Endocrinology · doi:10.1111/cen.13808 · Cited by 176
Androgen excess: Investigations and management
Lizneva, D., Gavrilova-Jordan, L. P., Walker, W., & Azziz, R. (2016) · Best Practice & Research Clinical Obstetrics & Gynaecology · doi:10.1016/j.bpobgyn.2016.05.003 · Cited by 175
Lai, Q., Xiang, W., Li, Q., Zhang, H., Li, Y., Zhu, G., Xiong, C., & Jin, L. (2018) · Frontiers of Medicine · doi:10.1007/s11684-017-0575-y · Cited by 175
Qu, F., Wang, F., Yin, R., Ding, G., Elprince, M., Gao, Q., Shi, B., Pan, H.-H., Huang, Y.-T., Jin, M., et al. (2012) · Journal of Molecular Medicine · doi:10.1007/s00109-012-0881-4 · Cited by 173
Effect of Diet on Insulin Resistance in Polycystic Ovary Syndrome
Shang, Y., Zhou, H., Hu, M., & Feng, H. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa425 · Cited by 171 · cited 2×
“Insulin stimulates adipogenesis and lipogenesis and inhibits lipolysis [42], resulting in fat accumulation [44].”
BackgroundSex hormone-binding globulin and polycystic ovary syndrome
Zhu, J.-L., Chen, Z., Feng, W.-J., Long, S.-L., & Mo, Z.-C. (2019) · Clinica Chimica Acta · doi:10.1016/j.cca.2019.09.010 · Cited by 169
Nutrition Strategy and Life Style in Polycystic Ovary Syndrome—Narrative Review
Szczuko, M., Kikut, J., Szczuko, U., Szydłowska, I., Nawrocka-Rutkowska, J., Ziętek, M., Verbanac, D., & Saso, L. (2021) · Nutrients · doi:10.3390/nu13072452 · Cited by 165
Polycystic ovary syndrome (PCOS) and endocrine disrupting chemicals (EDCs)
Palioura, E., & Diamanti-Kandarakis, E. (2015) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-016-9326-7 · Cited by 161
Nutrition in Gynecological Diseases: Current Perspectives
Ciebiera, M., Esfandyari, S., Siblini, H., Prince, L., Elkafas, H., Wojtyła, C., Al-Hendy, A. A., & Ali, M. K. (2021) · Nutrients · doi:10.3390/nu13041178 · Cited by 160
Polycystic ovary syndrome, adipose tissue and metabolic syndrome
Delitala, A. P., Capobianco, G., Delitala, G., Cherchi, P. L., & Dessole, S. (2017) · Archives of Gynecology and Obstetrics · doi:10.1007/s00404-017-4429-2 · Cited by 159
Insulin resistance and oxidative marker in women with PCOS
Bannigida, D. M., Nayak, B. S., & Vijayaraghavan, R. (2018) · Archives of Physiology and Biochemistry · doi:10.1080/13813455.2018.1499120 · Cited by 154
Nutritional management in women with polycystic ovary syndrome: A review study.
Faghfoori, Z., Fazelian, S., Shadnoush, M., & Goodarzi, R. (2017) · Diabetes & Metabolic Syndrome: Clinical Research & Reviews · doi:10.1016/j.dsx.2017.03.030 · Cited by 153
The diagnosis and treatment of PCOS in adolescents: an update
Witchel, S. F., Burghard, A. C., Tao, R., & Oberfield, S. E. (2019) · Current Opinion in Pediatrics · doi:10.1097/mop.0000000000000778 · Cited by 150
Zhang, R., Liu, H., Bai, H., Zhang, Y., Liu, Q., Guan, L., & Fan, P. (2016) · Clinical Endocrinology · doi:10.1111/cen.13171 · Cited by 144
Shedding new light on female fertility: the role of vitamin D
Muscogiuri, G., Altieri, B., de Angelis, C., Palomba, S., Pivonello, R., Colao, A., & Orio, F. (2017) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-017-9407-2 · Cited by 142
Recent advances in the understanding and management of polycystic ovary syndrome
Rocha, A. L., Oliveira, F. R., Azevedo, R. C., Silva, V. A., Peres, T. M., Candido, A. L., Gomes, K. B., & Reis, F. M. (2019) · F1000Research · doi:10.12688/f1000research.15318.1 · Cited by 142
Diagnosis of Polycystic Ovary Syndrome
Trivax, B., & Azziz, R. (2007) · Clinical Obstetrics & Gynecology · doi:10.1097/grf.0b013e31802f351b · Cited by 141
Hypothalamic–pituitary, ovarian and adrenal contributions to polycystic ovary syndrome
Baskind, N. E., & Balen, A. H. (2016) · Best Practice & Research Clinical Obstetrics & Gynaecology · doi:10.1016/j.bpobgyn.2016.03.005 · Cited by 131
Hyperandrogenic origins of polycystic ovary syndrome-Implications for Pathophysiology and Therapy
Abbott, D. H., Dumesic, D. A., & Levine, J. E. (2019) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2019.1576522 · Cited by 131 · cited 1×
“This receptor hypomethylation leads to higher gene expression and sensitivity to LH [18,20].”
BackgroundLifestyle and Behavioral Management of Polycystic Ovary Syndrome
Brennan, L., Teede, H. J., Skouteris, H., Linardon, J., Hill, B., & Moran, L. (2017) · Journal of Women s Health · doi:10.1089/jwh.2016.5792 · Cited by 128
Neuroendocrine Impairments of Polycystic Ovary Syndrome
Ruddenklau, A., & Campbell, R. E. (2019) · Endocrinology · doi:10.1210/en.2019-00428 · Cited by 125
Javed, Z., Papageorgiou, M., Deshmukh, H., Rigby, A. S., Qamar, U., Abbas, J., Khan, A. Y., Kilpatrick, E. S., Atkin, S. L., & Sathyapalan, T. (2019) · Clinical Endocrinology · doi:10.1111/cen.13968 · Cited by 121
Liu, Y., Yu, Z., Zhao, S., Cheng, L., Man, Y., Gao, X., & Zhao, H. (2020) · Journal of Assisted Reproduction and Genetics · doi:10.1007/s10815-020-02014-y · Cited by 121
Li, Y., Zheng, Q., Sun, D., Cui, X., Chen, S., Ahmmed, B., Liu, S., & Yan, Q. (2018) · Journal of Cellular Physiology · doi:10.1002/jcp.27501 · Cited by 120
Polycystic ovary syndrome: Understanding the role of the brain
Moore, A. M., & Campbell, R. E. (2017) · Frontiers in Neuroendocrinology · doi:10.1016/j.yfrne.2017.05.002 · Cited by 112
Polycystic ovary syndrome in adolescents
Rothenberg, S. S., Beverley, R. M., Barnard, E., Baradaran-Shoraka, M., & Sanfilippo, J. S. (2017) · Best Practice & Research Clinical Obstetrics & Gynaecology · doi:10.1016/j.bpobgyn.2017.08.008 · Cited by 107
HMGB1‐induced aberrant autophagy contributes to insulin resistance in granulosa cells in PCOS
Zhang, C., Hu, J., Wang, W., Sun, Y. W., & Sun, K. (2020) · The FASEB Journal · doi:10.1096/fj.202000605rr · Cited by 100
Zhang, X., Zheng, Y., Guo, Y., & Lai, Z. (2019) · International Journal of Endocrinology · doi:10.1155/2019/4386401 · Cited by 95
Polycystic Ovary Syndrome: Do Endocrine-Disrupting Chemicals Play a Role?
Sobolewski, M., & Barrett, E. S. (2014) · Seminars in Reproductive Medicine · doi:10.1055/s-0034-1371088 · Cited by 93
The physiological basis of complementary and alternative medicines for polycystic ovary syndrome
Raja-Khan, N. T., Stener‐Victorin, E., Wu, X., & Legro, R. S. (2011) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00667.2010 · Cited by 92
Docea, A. O., Vassilopoulou, L., Fragou, D., Arsene, A. L., Fenga, C., Kovatsi, L., Petrakis, D., Rakitskii, V. N., Nosyrev, A. E., Izotov, B. N., et al. (2017) · Toxicology Reports · doi:10.1016/j.toxrep.2017.05.007 · Cited by 91
Self-citationStepto, N. K., Moreno‐Asso, A., McIlvenna, L. C., Walters, K. A., & Rodgers, R. J. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2019-00167 · Cited by 89
Coyle, C., & Campbell, R. E. (2019) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2019.110561 · Cited by 89 · cited 2×
“HA disrupts the negative feedback on secretion [18,23,61,62] resulting in increased LH levels [18,62].”
BackgroundÖzer, A., Bakacak, M., Kıran, H., Ercan, Ö., Köstü, B., Pektas, M. K., Kılınç, M., & Aslan, F. (2016) · Ginekologia Polska · doi:10.5603/gp.2016.0079 · Cited by 86
Xu, Y., Wu, Y., & Huang, Q. (2017) · Archives of Gynecology and Obstetrics · doi:10.1007/s00404-017-4480-z · Cited by 86
Polycystic Ovary Syndrome-Epigenetic Mechanisms and Aberrant MicroRNA
Ilie, I. R. P., & Georgescu, C. E. (2015) · Advances in clinical chemistry · doi:10.1016/bs.acc.2015.06.001 · Cited by 84
Steegers-Theunissen, R. P. M., Wiegel, R. E., Jansen, P. W., Laven, J. S. E., & Sinclair, K. D. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21218211 · Cited by 82
Naka, K. Κ., Kalantaridou, S., Kravariti, M., Bechlioulis, A., Kazakos, N., Calis, K. A., Makrigiannakis, A., Katsouras, C. S., Chrousos, G. P., Tsatsoulis, A. A., et al. (2010) · Fertility and Sterility · doi:10.1016/j.fertnstert.2010.06.058 · Cited by 81
Avery, P. J., Jorgensen, A., Hamberg, A., Wadelius, M., Pirmohamed, M., & Kamali, F. (2011) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2011.186 · Cited by 78
Endocrine-metabolic dysfunction in polycystic ovary syndrome: An evolutionary perspective
Dumesic, D. A., Abbott, D. H., Sanchita, S., & Chazenbalk, G. D. (2020) · Current Opinion in Endocrine and Metabolic Research · doi:10.1016/j.coemr.2020.02.013 · Cited by 76
Tao, T., Zhang, Y., Zhu, Y., Fu, J.-R., Wang, Y., Cai, J., Ma, J., Xu, Y., Gao, Y., Sun, Y. W., et al. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa692 · Cited by 73
Polycystic Ovary Syndrome in Adolescence
Deans, R. (2019) · Medical Sciences · doi:10.3390/medsci7100101 · Cited by 72
Abdalla, M. A., Deshmukh, H., Atkin, S. L., & Sathyapalan, T. (2021) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/2042018821989238 · Cited by 72
Effects of myo-inositol plus alpha-lactalbumin in myo-inositol-resistant PCOS women
Oliva, M. M., Buonomo, G., Calcagno, M., & Unfer, V. (2018) · Journal of Ovarian Research · doi:10.1186/s13048-018-0411-2 · Cited by 71
Ortega, I., Villanueva, J. A., Wong, D. H., Cress, A. B., Sokalska, A., Stanley, S. D., & Dulęba, A. J. (2014) · Journal of Ovarian Research · doi:10.1186/1757-2215-7-21 · Cited by 60
Which origin for polycystic ovaries syndrome: Genetic, environmental or both?
Fénichel, P., Rougier, C., Hiéronimus, S., & Chevalier, N. (2017) · Annales d Endocrinologie · doi:10.1016/j.ando.2017.04.024 · Cited by 60
Jia, L., Feng, J., Li, J., Liu, F.-Y., Xie, L., Luo, S.-J., & Han, F. (2021) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2021/5555315 · Cited by 56
Mizgier, M., Jarząbek-Bielecka, G., Wendland, N., Jodłowska-Siewert, E., Nowicki, M., Brożek, A., Kędzia, W., Formanowicz, D., & Opydo-Szymaczek, J. (2021) · Nutrients · doi:10.3390/nu13030896 · Cited by 56
Pathomechanisms of polycystic ovary syndrome Multidimensional approaches
Mukherjee, S. (2018) · Frontiers in Bioscience-Elite · doi:10.2741/e829 · Cited by 53
Soave, I., Occhiali, T., Assorgi, C., Marci, R., & Caserta, D. (2020) · Current Medical Research and Opinion · doi:10.1080/03007995.2020.1729108 · Cited by 51
Shen, W., Jin, B., Pan, Y., Han, Y., You, T., Zhang, Z., Qu, Y., Liu, S., & Zhang, Y. (2021) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2021/6619597 · Cited by 49
Management of Endocrinopathies in Pregnancy: A Review of Current Evidence
Călina, D. C., Docea, A. O., Golokhvast, K. S., Sifakis, S., Tsatsakis, A. M., & Makrigiannakis, A. (2019) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph16050781 · Cited by 48
Self-citationPolycystic ovary syndrome in adolescents
Dabadghao, P. (2019) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2019.04.006 · Cited by 48
Uyanıkoğlu, H., Sabuncu, T., Dursun, H., Sezen, H., & Aksoy, N. (2016) · Biomarkers · doi:10.1080/1354750x.2016.1265004 · Cited by 46
Polycystic ovary syndrome management: a review of the possible amazing role of berberine
Rondanelli, M., Infantino, V., Riva, A., Petrangolini, G., Faliva, M. A., Peroni, G., Naso, M., Nichetti, M., Spadaccini, D., Gasparri, C., et al. (2020) · Archives of Gynecology and Obstetrics · doi:10.1007/s00404-020-05450-4 · Cited by 46
Hager, M., Nouri, K., Imhof, M., Egarter, C., & Ott, J. (2019) · Archives of Gynecology and Obstetrics · doi:10.1007/s00404-019-05194-w · Cited by 45
Probiotics as a Complementary Therapy for Management of Obesity: A Systematic Review
Shirvani-Rad, S., Tabatabaei‐Malazy, O., Mohseni, S., Hasani‐Ranjbar, S., Soroush, A., Tavassol, Z. H., Ejtahed, H., & Larijani, B. A. (2021) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2021/6688450 · Cited by 44
Sandhu, J. K., Waqar, A., Jain, A., Joseph, C. G., Srivastava, K., Ochuba, O., Alkayyali, T., Ruo, S. W., & Poudel, S. (2021) · Cureus · doi:10.7759/cureus.17887 · Cited by 41
Insulin resistance in polycystic ovary syndrome: concept versus cutoff
Greenwood, E. A., & Huddleston, H. G. (2019) · Fertility and Sterility · doi:10.1016/j.fertnstert.2019.08.100 · Cited by 40
Thomson, R. L., Spedding, S. J., Brinkworth, G. D., Noakes, M., & Buckley, J. D. (2013) · Fertility and Sterility · doi:10.1016/j.fertnstert.2012.12.042 · Cited by 38
Age-dependent endocrine disorders involved in the pathogenesis of refractory acne in women
Ianoși, S. L., Ianoși, G., Neagoe, D. C., Ionescu, O. M., Zlatian, O. M., Docea, A. O., Badiu, C., Sifaki, M., Tsoukalas, D., Tsatsakis, A. M., et al. (2016) · Molecular Medicine Reports · doi:10.3892/mmr.2016.5924 · Cited by 38
Self-citationRole of Statin Drugs for Polycystic Ovary Syndrome.
Cassidy-Vu, L., Joe, E., & Kirk, J. K. (2016) · PubMed Central · Cited by 38
Zhang, Y., Guo, X., Ma, S., Ma, H., Li, H., Wang, Y., Qin, Z., Wu, X., Han, Y., & Han, Y. (2021) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2021/6678398 · Cited by 36
Condorelli, R. A., Calogero, A. E., Mauro, M. D., & Vignera, S. L. (2017) · Gynecological Endocrinology · doi:10.1080/09513590.2017.1342240 · Cited by 35
Marinkovic-Radosevic, J., Cigrovski Berkovic, M., Kruezi, E., Bilic-Curcic, I., & Mrzljak, A. (2021) · World Journal of Diabetes · doi:10.4239/wjd.v12.i7.932 · Cited by 35 · cited 1×
“Exenatide (Byetta®) [121] Treatment of type II diabetes mellitus Nausea and vomiting, hypoglycemia, diarrhea, feeling jittery, dizziness, headache, dyspepsia History of a severe hypersensitivity reaction to the drug or any component of the formulation”
BackgroundIndustrial endocrine disruptors and polycystic ovary syndrome
Palioura, E., & Diamanti‐Kandarakis, E. (2013) · Journal of Endocrinological Investigation · doi:10.1007/bf03346762 · Cited by 34
Mohseni, M., Eghbali, M., Bahrami, H., Dastaran, F., & Amini, L. (2021) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2021/5564824 · Cited by 33
Drug Repurposing for the Management of Depression: Where Do We Stand Currently?
Sadeghi, H. M., Adeli, I., Mousavi, T., Daniali, M., Nikfar, S., & Abdollahi, M. R. (2021) · Life · doi:10.3390/life11080774 · Cited by 31
Self-citationZahradnik, H. P. (2005) · The European Journal of Contraception & Reproductive Health Care · doi:10.1080/13625180500434897 · Cited by 23
Segni, C. D., Silvestrini, A., Fato, R., Bergamini, C., Guidi, F., Raimondo, S., Meucci, E., Romualdi, D., Apa, R., Lanzone, A., et al. (2017) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/s-0043-111241 · Cited by 23
A Subpathway-Based Method of Drug Reposition for Polycystic Ovary Syndrome
Liu, H., Liu, J., Mai, Z., & Zeng, Y. (2014) · Reproductive Sciences · doi:10.1177/1933719114542025 · Cited by 16
Pharmacologic Treatment of Polycystic Ovary Syndrome: Alternate and Future Paths
Legro, R. S., & Martel‐Duguech, L. (2017) · Seminars in Reproductive Medicine · doi:10.1055/s-0037-1603729 · Cited by 12
Li, Y., Peng, C., Cao, G., Li, W., & Hou, L. (2018) · Trials · doi:10.1186/s13063-018-2893-z · Cited by 11
Yang, S., Yang, C., Pei, R., Li, Z., Li, X., Huang, X., Wu, S., & Liu, D. (2018) · Gynecological Endocrinology · doi:10.1080/09513590.2018.1460340 · Cited by 10
Hernández, E. (2020) · FARMACIA · doi:10.31925/farmacia.2020.6.19 · Cited by 8
Research works printed but not linked: 4
- Maloy, S., and Hughes, K. (2013). Epigenetics. Brenner’s Encyclopedia of Genetics, Academic Press. [2nd ed.].
- Worsfold, P., Poole, C., Townshend, A., and Miró, M. (2019). Endocrine Disrupting Chemicals. Encyclopedia of Analytical Science, Academic Press. [3rd ed.].
- Zeind, C.S., and Carvalho, M.G. (2017). Applied Therapeutics: The Clinical Use of Drugs, Wolters Kluwer Health.
- Mohseni, 2021, Yoga Effects on Anthropometric Indices and Polycystic Ovary Syndrome Symptoms in Women Undergoing Infertility Treatment: A Randomized Controlled Clinical Trial, Evid.-Based Complement. Altern. Med., 2021, 1, 10.1155/2021/5564824 · DOI
Cited by
Zhao, H., Zhang, J., Cheng, X., Nie, X., & He, B. (2023) · Journal of Ovarian Research · doi:10.1186/s13048-022-01091-0 · Cited by 408
The latest reports and treatment methods on polycystic ovary syndrome
Stańczak, N. A., Grywalska, E., & Dudzińska, E. (2024) · Annals of Medicine · doi:10.1080/07853890.2024.2357737 · Cited by 190
Ijaz, S., Iqbal, J., Abbasi, B. A., Ullah, Z., Yaseen, T., Kanwal, S., Mahmood, T., Sydykbayeva, S., Ydyrys, A., Almarhoon, Z. M., et al. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.114687 · Cited by 135
RetractedShrivastava, S., & Conigliaro, R. L. (2022) · Medical Clinics of North America · doi:10.1016/j.mcna.2022.10.004 · Cited by 102
Advances in the study of the correlation between insulin resistance and infertility
Lei, R., Chen, S., & Li, W. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1288326 · Cited by 92
Metadata
- Authors
- Sadeghi, H. M., Adeli, I., Calina, D., Docea, A. O., Mousavi, T., Daniali, M., Nikfar, S., Tsatsakis, A., & Abdollahi, M.
- Affiliations
- Pharmaceutical Sciences Research Center (IR)
- Department of Clinical Pharmacy, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania
- University of Medicine and Pharmacy of Craiova (RO)
- Personalized Medicine Research Center (IR)
- University of Crete (GR)
- Corresponding author
- Abdollahi, Mohammad
- ORCID
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2022-01-06
- Volume
- 23
- Issue
- 2
- Pages
- 583
- ISSN
- 1422-0067 (ISSN-L)
- PMC
- PMC8775814
- OpenAlex
- W4205636865
- Cited by
- 445
- References
- 106
- Citations by year
- 2026: 68 · 2025: 136 · 2024: 133 · 2023: 90 · 2022: 18
- FWCI
- 15.17
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- International Journal of Molecular Sciences (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Reproductive Medicine › Ovarian function and disorders
- Health Sciences › Medicine › Reproductive Medicine › Reproductive Biology and Fertility
- Health Sciences › Medicine › Reproductive Medicine › Endometriosis Research and Treatment
- Keywords
- polycystic ovary syndrome, PCOS pathogenesis, drug repurposing, insulin resistance, hyperandrogenism, oxidative stress, inflammation, obesity, epigenetics, environmental toxins, stress, diet, statins, thiazolidinediones, SGLT2 inhibitors, DPP-4 inhibitors, GLP-1 receptor agonists, mucolytic agents, lifestyle modification, complementary and alternative medicine
- MeSH terms
- Female, Humans, Insulin Resistance, Polycystic Ovary Syndrome, Hyperandrogenism, Disease Management, Drug Repositioning
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.